Clene (CLNN) Stock Forecast, Price Target & Predictions
CLNN Stock Forecast
Clene stock forecast is as follows: an average price target of $10.00 (represents a 48.37% upside from CLNN’s last price of $6.74) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
CLNN Price Target
The average price target for Clene (CLNN) is $10.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 48.37% upside from CLNN's last price of $6.74.
CLNN Analyst Ratings
According to 6 Wall Street analysts, Clene's rating consensus is 'Buy'. The analyst rating breakdown for CLNN stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Clene Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 02, 2022 | Sumant Kulkarni | Canaccord Genuity | $10.00 | $2.93 | 241.30% | 48.37% |
The latest Clene stock forecast, released on May 02, 2022 by Sumant Kulkarni from Canaccord Genuity, set a price target of $10.00, which represents a 241.30% increase from the stock price at the time of the forecast ($2.93), and a 48.37% increase from CLNN last price ($6.74).
Clene Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $6.74 | $6.74 | $6.74 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Clene stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Clene's last price of $6.74. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | EF Hutton | - | Buy | Initialise |
| Aug 06, 2024 | Rodman & Renshaw | Buy | Buy | Hold |
| Aug 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 23, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 17, 2024 | Benchmark | Underperform | Underperform | Hold |
| Apr 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 21, 2023 | Raymond James | Buy | Buy | Hold |
| Apr 10, 2023 | Benchmark | Buy | Buy | Hold |
Clene's last stock rating was published by EF Hutton on Sep 10, 2024. The company Initialise its CLNN rating from "null" to "Buy".
Clene Financial Forecast
Clene Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $170.00K | $108.00K | - | $107.00K | $234.00K | $174.00K | - | $30.00K | $199.00K | $110.00K | $201.00K | $213.00K |
| Avg Forecast | $100.00K | $100.00K | $100.00K | $100.00K | $143.33K | $106.67K | $120.00K | $162.50K | $145.00K | $136.00K | $117.83K | $134.17K | $181.00K | $86.67K | $83.33K | $83.00K | $116.25K | $116.25K | $100.00K | $209.75K |
| High Forecast | $100.00K | $100.00K | $100.00K | $100.00K | $143.33K | $106.67K | $120.00K | $162.50K | $165.71K | $136.00K | $117.83K | $134.17K | $181.00K | $86.67K | $83.33K | $88.19K | $123.52K | $123.52K | $106.25K | $222.86K |
| Low Forecast | $100.00K | $100.00K | $100.00K | $100.00K | $143.33K | $96.97K | $120.00K | $162.50K | $124.28K | $136.00K | $117.83K | $134.17K | $181.00K | $86.67K | $83.33K | $77.81K | $108.98K | $108.98K | $93.75K | $196.64K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | 1.17% | 0.79% | - | 0.80% | 1.29% | 2.01% | - | 0.36% | 1.71% | 0.95% | 2.01% | 1.02% |
Clene's average Quarter revenue forecast for Mar 24 based on 1 analysts is $162.50K, with a low forecast of $162.50K, and a high forecast of $162.50K. CLNN's average Quarter revenue forecast represents a -4.41% decrease compared to the company's last Quarter revenue of $170.00K (Dec 23).
Clene EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $-9.51M | $-9.54M | - | $-10.24M | $-10.21M | $-8.24M | - | $-12.71M | $4.80M | $29.19M | $-3.14M | $-39.03M |
| Avg Forecast | $-60.00K | $-60.00K | $-60.00K | $-60.00K | $-86.00K | $-64.00K | $-72.00K | $-97.50K | $-87.00K | $-81.60K | $-70.70K | $-80.50K | $-108.60K | $-52.00K | $-50.00K | $-10.00 | $-69.75K | $-69.75K | $-2.52M | $-125.85K |
| High Forecast | $-60.00K | $-60.00K | $-60.00K | $-60.00K | $-86.00K | $-58.18K | $-72.00K | $-97.50K | $-74.57K | $-81.60K | $-70.70K | $-80.50K | $-108.60K | $-52.00K | $-50.00K | $-8.00 | $-65.39K | $-65.39K | $-2.02M | $-117.98K |
| Low Forecast | $-60.00K | $-60.00K | $-60.00K | $-60.00K | $-86.00K | $-64.00K | $-72.00K | $-97.50K | $-99.43K | $-81.60K | $-70.70K | $-80.50K | $-108.60K | $-52.00K | $-50.00K | $-13.00 | $-74.11K | $-74.11K | $-3.03M | $-133.72K |
| Surprise % | - | - | - | - | - | - | - | - | 109.29% | 116.94% | - | 127.20% | 94.04% | 158.44% | - | 1271000.00% | -68.85% | -418.49% | 1.25% | 310.15% |
1 analysts predict CLNN's average Quarter EBITDA for Mar 22 to be $-10.00, with a high of $-8.00 and a low of $-13.00. This is -100.00% lower than Clene's previous annual EBITDA (Dec 21) of $4.80M.
Clene Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $-10.17M | $-2.42M | - | $-13.87M | $8.62M | $-12.13M | - | $-14.08M | $4.42M | $28.94M | $-3.35M | $-39.76M |
| Avg Forecast | $-133.60M | $-128.46M | $-136.17M | $-137.46M | $-126.26M | $-173.98M | $-193.77M | $-205.54M | $-184.99M | $-231.23M | $-316.86M | $-372.09M | $-88.09M | $61.41M | $-25.78M | $-11.00 | $-20.80M | $48.55M | $-2.69M | $-69.03M |
| High Forecast | $-133.60M | $-128.46M | $-136.17M | $-137.46M | $-126.26M | $-171.38M | $-193.77M | $-205.54M | $-158.56M | $-231.23M | $-316.86M | $-372.09M | $-88.09M | $73.69M | $-25.78M | $-9.00 | $-19.11M | $58.26M | $-2.15M | $-63.42M |
| Low Forecast | $-133.60M | $-128.46M | $-136.17M | $-137.46M | $-126.26M | $-175.28M | $-193.77M | $-205.54M | $-211.41M | $-231.23M | $-316.86M | $-372.09M | $-88.09M | $49.13M | $-25.78M | $-14.00 | $-22.49M | $38.84M | $-3.23M | $-74.64M |
| Surprise % | - | - | - | - | - | - | - | - | 0.05% | 0.01% | - | 0.04% | -0.10% | -0.20% | - | 1280181.82% | -0.21% | 0.60% | 1.25% | 0.58% |
Clene's average Quarter net income forecast for Mar 23 is $-372.09M, with a range of $-372.09M to $-372.09M. CLNN's average Quarter net income forecast represents a -4419.15% decrease compared to the company's last Quarter net income of $8.62M (Dec 22).
Clene SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $3.32M | $3.67M | - | $3.18M | $4.26M | $3.34M | - | $4.38M | $2.07M | $4.40M | $6.95M | $5.39M |
| Avg Forecast | $2.19M | $2.19M | $2.19M | $2.19M | $3.14M | $2.34M | $2.63M | $3.56M | $3.17M | $2.98M | $2.58M | $2.94M | $3.96M | $1.90M | $1.82M | $4.00 | $2.55M | $2.55M | $2.19M | $4.59M |
| High Forecast | $2.19M | $2.19M | $2.19M | $2.19M | $3.14M | $2.34M | $2.63M | $3.56M | $3.63M | $2.98M | $2.58M | $2.94M | $3.96M | $1.90M | $1.82M | $5.00 | $2.70M | $2.70M | $2.33M | $4.88M |
| Low Forecast | $2.19M | $2.19M | $2.19M | $2.19M | $3.14M | $2.12M | $2.63M | $3.56M | $2.72M | $2.98M | $2.58M | $2.94M | $3.96M | $1.90M | $1.82M | $3.00 | $2.39M | $2.39M | $2.05M | $4.31M |
| Surprise % | - | - | - | - | - | - | - | - | 1.05% | 1.23% | - | 1.08% | 1.07% | 1.76% | - | 1093750.00% | 0.81% | 1.73% | 3.17% | 1.17% |
Clene's average Quarter SG&A projection for Mar 24 is $3.56M, based on 1 Wall Street analysts, with a range of $3.56M to $3.56M. The forecast indicates a 7.10% rise compared to CLNN last annual SG&A of $3.32M (Dec 23).
Clene EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | $-0.08 | $-0.02 | - | $-0.18 | $0.13 | $-0.19 | - | $-0.22 | $0.07 | $0.47 | $-0.05 | $-0.66 |
| Avg Forecast | $-1.04 | $-1.00 | $-1.06 | $-1.07 | $-0.98 | $-1.35 | $-1.51 | $-1.60 | $-1.44 | $-1.80 | $-2.47 | $-2.90 | $-0.69 | $-4.31 | $-0.20 | $-0.20 | $-0.16 | $-0.20 | $-0.15 | $-0.54 |
| High Forecast | $-1.04 | $-1.00 | $-1.06 | $-1.07 | $-0.98 | $-1.33 | $-1.51 | $-1.60 | $-1.23 | $-1.80 | $-2.47 | $-2.90 | $-0.69 | $-4.31 | $-0.20 | $-0.18 | $-0.15 | $-0.19 | $-0.14 | $-0.49 |
| Low Forecast | $-1.04 | $-1.00 | $-1.06 | $-1.07 | $-0.98 | $-1.36 | $-1.51 | $-1.60 | $-1.65 | $-1.80 | $-2.47 | $-2.90 | $-0.69 | $-4.31 | $-0.20 | $-0.21 | $-0.18 | $-0.22 | $-0.17 | $-0.58 |
| Surprise % | - | - | - | - | - | - | - | - | 0.06% | 0.01% | - | 0.06% | -0.19% | 0.04% | - | 1.13% | -0.44% | -2.33% | 0.32% | 1.23% |
According to 1 Wall Street analysts, Clene's projected average Quarter EPS for Mar 23 is $-2.90, with a low estimate of $-2.90 and a high estimate of $-2.90. This represents a -2328.08% decrease compared to CLNN previous annual EPS of $0.13 (Dec 22).
Clene Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.57 | $17.50 | 2970.18% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| NGM | NGM Biopharmaceuticals | $1.54 | $16.50 | 971.43% | Buy |
| SNSE | Sensei Biotherapeutics | $0.54 | $5.50 | 918.52% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| HOWL | Werewolf Therapeutics | $2.34 | $12.00 | 412.82% | Buy |
| NKTX | Nkarta | $5.71 | $21.60 | 278.28% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| IMNM | Immunome | $15.97 | $30.33 | 89.92% | Buy |
| FHTX | Foghorn Therapeutics | $9.72 | $18.00 | 85.19% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| CLNN | Clene | $6.74 | $10.00 | 48.37% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
CLNN Forecast FAQ
Is Clene a good buy?
Yes, according to 6 Wall Street analysts, Clene (CLNN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of CLNN's total ratings.
What is CLNN's price target?
Clene (CLNN) average price target is $10 with a range of $10 to $10, implying a 48.37% from its last price of $6.74. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Clene stock go up soon?
According to Wall Street analysts' prediction for CLNN stock, the company can go up by 48.37% (from the last price of $6.74 to the average price target of $10), up by 48.37% based on the highest stock price target, and up by 48.37% based on the lowest stock price target.
Can Clene stock reach $10?
CLNN's average twelve months analyst stock price target of $10 does not support the claim that Clene can reach $10 in the near future.
What are Clene's analysts' financial forecasts?
Clene's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $532.5K (high $532.5K, low $522.8K), average EBITDA is $-319K (high $-314K, low $-319K), average net income is $-700M (high $-697M, low $-701M), average SG&A $11.66M (high $11.66M, low $11.45M), and average EPS is $-5.445 (high $-5.425, low $-5.456). CLNN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $400K (high $400K, low $400K), average EBITDA is $-240K (high $-240K, low $-240K), average net income is $-536M (high $-536M, low $-536M), average SG&A $8.76M (high $8.76M, low $8.76M), and average EPS is $-4.17 (high $-4.17, low $-4.17).
Did the CLNN's actual financial results beat the analysts' financial forecasts?
Based on Clene's last annual report (Dec 2023), the company's revenue was $654K, beating the average analysts forecast of $533K by 22.70%. Apple's EBITDA was $-40.54M, beating the average prediction of $-320K by 12576.71%. The company's net income was $-49.504M, missing the average estimation of $-1.105B by -95.52%. Apple's SG&A was $14.42M, beating the average forecast of $11.67M by 23.55%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-8.603 by -99.99%. In terms of the last quarterly report (Dec 2023), Clene's revenue was $170K, beating the average analysts' forecast of $145K by 17.24%. The company's EBITDA was $-9.508M, beating the average prediction of $-87K by 10828.74%. Clene's net income was $-10.173M, missing the average estimation of $-185M by -94.50%. The company's SG&A was $3.32M, beating the average forecast of $3.17M by 4.64%. Lastly, the company's EPS was $-0.0792, missing the average prediction of $-1.44 by -94.50%